NCT01498588TERMINATEDanonymous

Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Sponsor

Source record

Emory University

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim

Indication / condition

AI-normalized

Breast Neoplasms

Intervention

Source record

Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim

Source & freshness

Source record

NCT ID

NCT01498588

Original source

ClinicalTrials.gov

Source last updated

Oct 03, 2016

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01498588

Title

Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Sponsor

Emory University

Status

TERMINATED

Phase

PHASE2

Condition raw

Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast, Neoplasms, Breast, Tumors, Breast

Condition normalized

Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast, Neoplasms, Breast, Tumors, Breast

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim

Target normalized

Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim

Interventions

Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim

Public preview

Source record

Previous studies have shown that chemotherapy has the same effect on treating breast cancer whether you receive it before or after surgery. Receiving chemotherapy before surgery, rather than after surgery, may allow the patient to have less extensive surgery. The purpose of this study is to identify new treatment regimens with better response rates and to find out if the combination of eribulin followed by doxorubicin and cyclophosphamide can shrink the size of the patient's breast tumor and allow you to preserve your breast. Additionally, by receiving chemotherapy before surgery, the investigators will be able to determine if your cancer is responsive to chemotherapy.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01498588

Status

TERMINATED

Phase

PHASE2

Sponsor

Emory University

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedOct 03, 2016

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01498588

Indication

Breast Neoplasms

Modality

small molecule

Target

Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim

Intervention

Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.